Article Excerpt: Wysa, an artificial intelligence (AI) based digital companion for behavioural health, has been granted Breakthrough Device Designation by the Food and Drug Administration (FDA) for its AI-based digital mental health conversational agent for patients 18 years and older with a diagnosis of chronic musculoskeletal pain (defined as pain lasting longer than three months) and depression and anxiety. The device delivers cognitive behavioural therapy (CBT) via a smartphone-based conversational agent to reduce the symptoms of depression and anxiety, reduce pain interference, and improve physical function.
Full Article: https://tinyurl.com/2kz3nvsk
Article Source: Med-Tech Innovation News